Evidence map›Paper›PMID 29843632›Full record

ArticleBMC infectious diseases2018

Faecal colonization of E. coli and Klebsiella spp. producing extended-spectrum beta-lactamases and plasmid-mediated AmpC in Mozambican university students.

L M Chirindze, T F Zimba, J O Sekyere, U Govinden, H Y Chenia, A Sundsfjord, S Y Essack, G S Simonsen

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 5 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Genomic insights into extended-spectrumJournal of medical microbiology · 2025
    Article
  8. Article
  9. Polyclonal Multidrug ESBL-ProducingAntibiotics (Basel, Switzerland) · 2023
    Article
  10. Article
  11. Article
  12. Detection of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Antimicrobial Resistance inFrontiers in medicine · 2021
    Review
  18. Molecular Epidemiology of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

L M ChirindzeMicrobiology Laboratory, Maputo Central Hospital, Maputo, Mozambique.
T F ZimbaMicrobiology Laboratory, Maputo Central Hospital, Maputo, Mozambique.
J O SekyereAntimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
U GovindenAntimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
H Y CheniaDiscipline of Microbiology, School of Life Sciences, University of KwaZulu-Natal, Durban, South Africa.
A SundsfjordAntimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
S Y EssackAntimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
G S SimonsenAntimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. gunnar.skov.simonsen@unn.no.ORCID 0000-0003-0043-7045
University of KwaZulu-Natal · ZAMaputo Central Hospital · MZUiT The Arctic University of Norway · NOUniversity Hospital of North Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn recent years, the world has seen a surge in Enterobacteriaceae resistant to broad-spectrum beta-lactam antibiotics due to the production of extended-spectrum beta-lactamases (ESBLs) or plasmid-mediated AmpC (pAmpC) enzymes. Data on the epidemiology of cephalosporin-resistant Enterobacteriaceae in Sub-Saharan Africa are still limited.

methodsTwo hundred seventy-five non-repetitive stool samples were collected from Mozambican university students of both sexes. Samples were cultured on MacConkey agar with and without ceftriaxone (1 mg/L) for selection of third-generation cephalosporin-resistant isolates, which were subjected to antimicrobial susceptibility testing by disc diffusion, characterization of resistance genes by PCR and ERIC-PCR analysis for strain clonality.

resultsAmong the 275 students, 55 (20%) carried a total of 56 E. coli (n = 35) and Klebsiella spp. (n = 21) isolates resistant to ceftriaxone and phenotypically positive for ESBL- and/or pAmpC-production. Forty-three percent of the isolates (24/56) contained only ESBL genes, 11% (6/56) only pAmpC genes, and 36% (20/56) both ESBL and pAmpC genes. The remaining six isolates were negative for the CTX-M/pAmpC genes included in the test panel. E. coli and Klebsiella spp. combined demonstrated 70% resistance to tetracycline and co-trimoxazole, 63% to ceftazidime and 34% to ciprofloxacin. In total, 89% of ESBL/pAmpC-positive isolates were defined as multi-resistant by being resistant to three or more antibiotic classes. ERIC-PCR fingerprinting demonstrated low similarity among isolates. None of the participants reported recent hospitalization and just 12.5% had taken antibiotics 3 months prior to the study.

conclusionThis study demonstrated 20% colonization with multi-resistant E. coli and Klebsiella spp. among Mozambican students with a diversity of ESBL and pAmpC genes. Colonization was not related to prior hospitalization or antimicrobial consumption.

Indexed as

AdultAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesDrug Resistance, Multiple, BacterialEscherichia coliEscherichia coli InfectionsFecesFemaleHumansKlebsiellaKlebsiella InfectionsMaleMicrobial Sensitivity TestsMozambiquePlasmidsAmpC beta-lactamasesAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesColonizationE. coliESBLKlebsiellaMozambiquepAmpCStudents

Identifiers

PMID29843632
PMCPMC5975407
OpenAlexW2806590405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.